Imperial College London

DrGrahamClarke

Faculty of MedicineNational Heart & Lung Institute

Honorary Senior Lecturer
 
 
 
//

Contact

 

g.clarke

 
 
//

Location

 

Guy Scadding BuildingRoyal Brompton Campus

//

Summary

 

Summary

Graham Clarke is Head of Translational Science & Experimental Medicine Operations, Early Respiratory & Immunology at AstraZeneca, and Honorary Senior Lecturer at the National Heart & Lung Institute.   Graham contributes  to the delivery of the MSc Genes, Drugs and Stem Cells programme with a focus on principles of precision medicine in respiratory disease; drug development investment criteria- triaging a target to a drug to market ; responder non- responder classification; utility of non-invasive markers of inflammation and inhaled challenge models – linking pre-clinical modelling to Human inflammatory mechanisms.

In 2022 he co-authored the abstract “To Game or Not to Game- That is The Question: Evaluation of newly developed gamification elements in MSc Pharmacology, which won the British Pharmacological Society Best Educational Poster prize 2022.

 Graham was awarded his doctorate in 2006 from King’s College London focusing on the importance of the airway vasculature in asthma and was awarded an ERS Young Scientist Award for his work on the Involvement of the airway vasculature in the late asthmatic response (LAR) to allergen.

After almost 25 years working across both academic, contract research and biopharma organisations, Graham is considered an expert in the deployment of translational and precision medicine strategy in Respiratory & Immunology clinical trials with specific focus on inhaled challenge models and minimally invasive precision sampling notably in nasal, sputum sampling and exhaled breath markers of disease.  During his time at AstraZeneca, he has built the operating infrastructures to enable and communicate the precision medicine strategy for the early R&I portfolio from target identification to phase 3 studies.  His team drives initiatives to develop strategic collaborations and partnering both internally and externally across industry and academia, developing AstraZeneca’s global reach to improve the lives of patients, making precision medicine a reality for the treatment of Respiratory and Immunology conditions.